Wall Street Jedi
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Wall Street Jedi
No Result
View All Result
Home Investing

Kennedy would keep legal fees from Merck cases if confirmed

by
January 23, 2025
in Investing
0
Kennedy would keep legal fees from Merck cases if confirmed
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

By Dan Levine and Mike Spector

(Reuters) – Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck (NSE:PROR) if he is confirmed as President Donald Trump’s secretary of the U.S. Department of Health and Human Services, according to a federal ethics disclosure made public on Wednesday.

Kennedy, who ended his own presidential campaign last year to endorse Trump, is set for a U.S. Senate hearing on his nomination next week. As HHS secretary, Kennedy would wield enormous influence over the pharma industry, and the nomination is opposed by several health and consumer organizations over Kennedy’s role in sowing doubt about the safety and efficacy of vaccines.

Reuters reported last week that Kennedy played an instrumental role in organizing mass litigation against Merck over its human papillomavirus shot Gardasil. One of the main lawyers suing Merck, Michael Baum, told Reuters that Kennedy “taught us” how to pursue Gardasil claims outside a special government-run vaccine compensation program that limits pharma company liability.

Kennedy has an arrangement to earn 10 percent of fees awarded in contingency cases he refers to Baum’s firm WisnerBaum, according to a letter Kennedy wrote to an HHS ethics official released on Wednesday. If confirmed, Kennedy would retain that financial interest in cases that do not directly impact the U.S. government, the letter said.

Kennedy and Baum did not immediately respond to requests for comment. Merck declined to comment.

High-level U.S. government officials routinely disclose financial interests and potential conflicts during the nomination process.

Kennedy wrote that he is “not an attorney of record” for his WisnerBaum cases. However, Kennedy filed official court appearances in several Gardasil cases, including one set for trial in Los Angeles this week, court dockets show. As of Wednesday, Kennedy had not appeared to have withdrawn from them.

In a separate ethics disclosure, Kennedy reported at least $857,000 from WisnerBaum, and did not specify which cases generated that income. Kennedy has collaborated with WisnerBaum on litigation over Monsanto (NYSE:MON)’s weed killer Roundup.

The Gardasil lawsuits allege Merck had fraudulently advertised the vaccine as safe, overstating its benefits while concealing knowledge of dangerous side effects. Merck says the cases have no merit and that research supports the safety of its HPV vaccines.

This post appeared first on investing.com
Previous Post

Senate Finance chair hoping for Bessent confirmation vote next week

Next Post

Saudi crown prince seeks $600 billion investment push with U.S.

Next Post
Saudi crown prince seeks $600 billion investment push with U.S.

Saudi crown prince seeks $600 billion investment push with U.S.

  • Trending
  • Comments
  • Latest
American creating deepfakes targeting Harris works with Russian intel, documents show

American creating deepfakes targeting Harris works with Russian intel, documents show

October 23, 2024
Cadence raises midpoint of 2024 profit forecast on robust demand from chip designers

Cadence raises midpoint of 2024 profit forecast on robust demand from chip designers

October 28, 2024
Earnings call: Microsoft sees soaring cloud and AI growth in Q1 FY2025

Earnings call: Microsoft sees soaring cloud and AI growth in Q1 FY2025

October 31, 2024
Israel stocks lower at close of trade; TA 35 down 0.23%

Israel stocks lower at close of trade; TA 35 down 0.23%

October 6, 2024
Sports executive charged with bid-rigging in Texas arena project

Sports executive charged with bid-rigging in Texas arena project

0
Retailers scramble to move billions in cargo as East Coast dockworkers prepare to strike

Retailers scramble to move billions in cargo as East Coast dockworkers prepare to strike

0
PepsiCo to buy tortilla chip maker Siete Foods for $1.2 billion

PepsiCo to buy tortilla chip maker Siete Foods for $1.2 billion

0
East and Gulf coast ports shut down as thousands of workers go on strike

East and Gulf coast ports shut down as thousands of workers go on strike

0
Sports executive charged with bid-rigging in Texas arena project

Sports executive charged with bid-rigging in Texas arena project

July 10, 2025
OpenAI to release web browser in challenge to Google Chrome

OpenAI to release web browser in challenge to Google Chrome

July 10, 2025
Amazon extends Prime Day discounts to 4 days as retailers weigh tariffs and price increases

Amazon extends Prime Day discounts to 4 days as retailers weigh tariffs and price increases

July 9, 2025
Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

July 9, 2025

Recent News

Sports executive charged with bid-rigging in Texas arena project

Sports executive charged with bid-rigging in Texas arena project

July 10, 2025
OpenAI to release web browser in challenge to Google Chrome

OpenAI to release web browser in challenge to Google Chrome

July 10, 2025
Amazon extends Prime Day discounts to 4 days as retailers weigh tariffs and price increases

Amazon extends Prime Day discounts to 4 days as retailers weigh tariffs and price increases

July 9, 2025
Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

Boeing delivers most airplanes since late 2023 after ramping up 737 Max output

July 9, 2025

Disclaimer: WallStreetJedi.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 wallstreetjedi.com | All Rights Reserved

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 wallstreetjedi.com | All Rights Reserved